The EMA’s human medicines advisory committee has recommended approval of Eli Lilly’s Baqsimi ... Baqsimi is a nasal spray formulation of glucagon, already widely used as an injectable ...

Glucagon is a recognised therapy for the ... which was approved in 2019 as a hypoglycaemia rescue therapy for diabetics. Eli Lilly's nasal spray Baqsimi was also approved in 2019 for a similar ...

Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss medications. Lilly filed four lawsuits on Wednesday claiming telehealth ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Eli Lilly has filed a lawsuit against four telehealth platforms selling compounded versions of its blockbuster metabolic disorder drug tirzepatide, marking the latest power struggle between weight ...

Pharmaceutical company Eli Lilly announced promising clinical trial results for a daily pill to treat obesity and diabetes, a ...

Eli Lilly stock has been a big-time winner ... has been the blockbuster drugs Mounjaro and Zepbound. These are Lilly's glucagon-like peptide-1 (GLP-1) medicines, which compete directly with ...

Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly (NYSE ... drugs Mounjaro and Zepbound. These are Lilly's glucagon-like peptide-1 (GLP-1) medicines, which ...

The weight loss drug market could grow to $500 billion over the next decade. Eli Lilly's next-generation products look promising, while competitors have stumbled in clinical trials. Investors are ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...

It's Thursday morning, 11:50 a.m. ET -- and Eli Lilly (NYSE ... Phase 3 trial." As Lilly described in its press release, orforglipron is "the first oral small molecule glucagon-like peptide ...